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Introduction
Discussion
• Sexual and gender minority (SGM) individuals experience higher rates 
of substance use disorders (SUDs) compared to heterosexual, 
cisgender individuals1
• SGM individuals with multiple minority statuses--such as racial 
minorities, people living with HIV (PLWH) or individuals with low 
socioeconomic status (SES)--may be at an even higher risk for SUDs2,3
• Syndemics Theory4 and Minority Stress Theory5 can contextualize 
these higher SUD rates
• Participants: 60 adult PLWH (SGM and non-SGM) recruited from an
abstinence-focused, residential treatment center in Washington,
D.C.
• Procedures and Measures: Data for this study were taken from a
larger, randomized clinical trial which assessed a behavioral
activation intervention administered by PhD level trainees with
multicultural training
• SGM Status. Participants who self identified as gay, lesbian,
bisexual, and/or transgender were considered SGM
• Participants completed 16 sessions and were followed over 12
months post treatment to assess:
• Substance Use. Assessed via:
• Dichotomous Assessment. Yes/no according to Timeline
Follow Back (TLFB) and urinalysis results
• Frequency of Use. Number of days used divided by total
days in assessment period using TLFB data
• Substance Use Related Problems. Measured using the Short
Inventory of Problems-Alcohol and Drugs (SIP-AD)
• Participants (n=61 in study; n=60 with defined SGM status; n=56 
included in survival analysis)
• >95% African American
• >90% unemployed
• n=21 self-identified as SGM; n=35 identified as non-SGM
• SGM participants significantly younger (42.38 vs. 47.0 years) with 
more prior treatment episodes (4.70 vs. 2.68 episodes)
• Overall sample
• At the end of the 12-month follow-up, 20.5% of participants who 
were at risk had not returned to substance use (survival rate)
• Problems associated with use decreased over time (Estimate =      
-.76, p<.001) 
• Time to substance reuse
• Overall time to event model was significant (𝜆!= 25.46, p<.001)
• Non-SGM survival rate= 37.5%; SGM survival rate= 4.8%
• SGM individuals have 1.88 [95% CI: .84, 4.19] times the odds of 
reuse compared to non-SGM individuals 
• Frequency of use
• In SGM-only model, SGM status was a significant predictor of 
the model intercept (log odds = 3.62, p=.02)
• Frequency of use was greater on average for the SGM group at
baseline (residential discharge) (non-SGM intercept= -7.94 →
0.04% days used; SGM intercept= -4.33 → 1.3% days used)
• In final multivariate model, SGM status was not a significant
predictor (log odds= 2.46, p= .14)
• Substance use related problems
• No effect of SGM status on substance use related problems in
any model
• Focus on a complex, multiple minority PLWH population
• Focus on a complex intervention in an inpatient/outpatient clinical
setting
• Examine how SGM status impacts:
• Time to substance reuse (via a discrete time survival analysis)
• Frequency of use (via a trajectory analysis*)
• Substance use related problems (via a trajectory analysis*)
*Analyzed an SGM-only model and a final multivariate model that controlled for age and
number of prior treatment episodes
• Findings suggest an almost two times increase in the odds of reuse 
for those who identify as SGM (though not significant)
• Not a statistically significant finding, perhaps due to: 
• Small sample size
• Too short of a follow-up period
• Yet, these results are notable, supporting the need for SGM and 
multiple minority specialized care 
• Despite the strengths of the longitudinal design, future work must:
• Replicate these findings in a larger sample
• Measure stigma and other SGM-relevant variables
• Examine providers with normative training
• PhD level trainees may have more multicultural training than 
the average substance use treatment provider
• Consider harm reduction instead of abstinence-only-focused care
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